RSS   Newsletter   Contact   Advertise with us

Audentes Therapeutics adds Julie Anne Smith to board

Share on Twitter Share on LinkedIn
Staff Writer | San Francisco, Ca., USA | December 14, 2016
Julie Anne SmithDecember 14, 2016, San Francisco, Ca., USA - Audentes Therapeutics, a biotechnology company, announced the appointment of Julie Anne Smith to its board of directors.
Ms. Smith served as President and Chief Executive Officer of Raptor Pharmaceuticals, Inc. from January 2015 until the company's recent acquisition by Horizon Pharma plc.

Previously, Ms. Smith served as Raptor's Executive Vice President and Chief Operating Officer after joining the company in September 2012.

From 2008 to 2012, Ms. Smith served as Chief Commercial Officer of Enobia Pharma Corporation, prior to the company's acquisition by Alexion.

Additionally, she served in positions of increasing responsibility at Jazz Pharmaceuticals plc (2006-2008), Genzyme, Inc. (2001-2005) and Novazyme Pharmaceuticals, Inc. (2000-2001).

Ms. Smith began her industry career at Bristol-Myers Squibb, first as a Product Manager and later as Director of channel strategy and design.

She serves as an Independent Director at Exelixis, Inc. and previously as Director on the Health and Emerging Companies Sections of the Biotechnology Industry Organization (BIO) board.

She received her Bachelor of Science in biological and nutritional sciences from Cornell University.